Industry
Biotechnology
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Loading...
Open
49.91
Mkt cap
3.3B
Volume
290K
High
51.13
P/E Ratio
-21.77
52-wk high
53.27
Low
49.39
Div yield
N/A
52-wk low
13.85
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 7:33 pm
Portfolio Pulse from Benzinga Insights
November 01, 2024 | 5:01 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 2:46 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 1:37 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 11:34 am
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 9:03 pm
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 8:04 pm
Portfolio Pulse from Vandana Singh
October 30, 2024 | 7:12 pm
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:35 am
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 11:20 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.